EMA's draft policy on data transparency may have the unintended consequence of jeopardizing data exclusivity in non-European jurisdictions, according to two lawyers on the industry side of the issue.

EMA has proposed to proactively publish a large amount of clinical trial data following a decision on marketing authorization, and to make raw patient-level data available through a controlled access system (see BioCentury, July 22).